Zacks Analyst Blog Highlights: U.S. Cellular, Telephone & Data Systems, CV Therapeutics and Priceline.com.CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day, the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: U.S. Cellular U.S. Cellular (NYSE: USM) is a super-regional cellular telephone provider, serving 5.8 million customers in 189 markets in 26 U.S. states. The company was created in 1983 as a subsidiary of Telephone and Data Systems, Inc. Since April 2000, John E. (AMEX AMEX See: American Stock Exchange : USM USM abbr. 1. United States Mail 2. United States Mint USM n abbr (= United States Mint) → US-Münzanstalt (= United States Mail) → US-Postbehörde ), Telephone & Data Systems (NYSE NYSE See: New York Stock Exchange : TDS TDS total dissolved solids. ), CV Therapeutics (Nasdaq: CVTX) and Priceline.com (Nasdaq: PCLN PCLN Priceline.com (stock abbreviation, AMEX) ). See the latest posts to the Analyst Blog by visiting: http://at.zacks.com/?id=2673 Here are highlights from Wednesday's Analyst Blog: Keep a Sell on USM Financial reporting delays at U.S. Cellular (AMEX: USM) have intensified the risk and uncertainty associated with the relatively high valuation. Over the near-term, we do not believe U.S. Cellular would be a part of consolidation activities, outside of Telephone & Data Systems (NYSE: TDS) full ownership. But the stock has moved up in anticipation of a buyout offer from parent TDS. However, given that TDS already controls most of the shares outstanding, it is unlikely that it will have to pay a large premium for the remaining shares of USM. Recently, USM released its fourth quarter 2005 results, which were disappointing. We maintain our Sell recommendation based on the current valuation level, timing uncertainty of audited financial information, and our expectations that share demand may be in a near-term decline until complete financials are presented. CVTX Maintains $16 Target Headquartered in Palo Alto Palo Alto, city, California Palo Alto (păl`ō ăl`tō), city (1990 pop. 55,900), Santa Clara co., W Calif.; inc. 1894. Although primarily residential, Palo Alto has aerospace, electronics, and advanced research industries. , CA, CV Therapeutics (Nasdaq: CVTX) is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. Second quarter sales of Ranexa launched in March for chronic angina were extremely disappointing. Uptake will probably remain low until the MERLIN data becomes available in the first quarter of 2007. Nevertheless, we continue to rate the shares a Buy based on our belief that MERLIN will be positive and use in the first-line indication and acute coronary syndrome acute coronary syndrome n. A sudden, severe coronary event that mimics a heart attack, such as unstable angina. acute coronary syndrome (ACS (Asynchronous Communications Server) See network access server. ) will drive significant profitably in 2010. We are maintaining our price target of $16. Momentum at Priceline Business momentum remains strong at Priceline.com (Nasdaq: PCLN), and the company upped its earnings per share guidance for the third quarter from $0.60-$0.64 to $0.64-$0.68. Priceline.com's international business expansion and increased retail offerings continue to be the primary drivers of its overall growth. Despite the shares being up 62% year-to-date (and up 66% since our upgrade on February 1), we still believe the shares trade at an attractive value. We reiterate our Buy rating and increase our target price from $35 to $42 to reflect the stronger-than-expected growth. Priceline.com is scheduled to report third quarter results on or about November 8. See the latest posts to the Analyst Blog by visiting http://at.zacks.com/?id=2645 About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis Qualitative Analysis Securities analysis that uses subjective judgment based on nonquantifiable information, such as management expertise, industry cycles, strength of research and development, and labor relations. to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to Verb 1. subscribe to - receive or obtain regularly; "We take the Times every day" subscribe, take buy, purchase - obtain by purchase; acquire by means of a financial transaction; "The family purchased a new car"; "The conglomerate acquired a new company"; this free newsletter today by visiting http://at.zacks.com/?id=2674. About Zacks Zacks.com is a property of Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. , Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion